$KPRX
Kiora Pharmaceuticals, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$1.66
▲After hours+0.00%+$0.000After hours
Kiora Pharmaceuticals, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is KPRX down today? It is at $1.66 (-4.05%), and our scanner flagged it 8 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment KPRX spikes, and full due diligence on KPRX — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $KPRX 8 times in the last 30 days. Create a free account to track $KPRX, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on KPRX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for KPRX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalyst•The oral small-molecule calpain inhibitor demonstrated meaningful visual acuity improvement in Phase 2 and Phase 3 CRAO studies conducted in Japan compared to controls.Reported The oral small-molecule calpain inhibitor demonstrated meaningful visual acuity improvement in Phase 2 and Phase 3 CRAO studies conducted in Japan compared to controls.Reported Kiora plans to advance KIO-401 (mitucapistat) into a multinational Phase 3 registration trial in CRAO, with initiation targeted for 2027.Reported Company also plans to evaluate KIO-401 in a Phase 2b clinical trial in non-arteritic anterior ischemic optic neuropathy (“NAION”)., from the latest SEC filing. Read it →Across every filing on file, supply equal to 819.9% of the tradeable float is in play - 725.5% has already been sold, and 94.4% more can still be issued.
Shelf sizes are dollars, so shares are estimated at today's price.
One filing exceeds the whole float, which usually means our share count is stale. Check the filing directly.
Recent share offering + active shelf on file — the company raised capital and can raise more
23,155,705 new shares · About $5.0M in size
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Strem Brian M. Officer | Sold (automatic/other) | -2K 0.04% of company | sold 3.1% | 59K | $5K at $2.66 | Jul 1, 26 |
Tosca Melissa Officer | Sold (automatic/other) | -911 0.02% of company | sold 3.4% | 26K | $2K at $2.66 | Jul 1, 26 |
Strem Brian M. Officer | Sold (automatic/other) | -2K 0.04% of company | sold 3.0% | 61K | $4K at $1.95 | Apr 1, 26 |
Daniels Eric Joseph Officer | Sold (automatic/other) | -929 0.02% of company | sold 2.8% | 32K | $2K at $1.95 | Apr 1, 26 |
Tosca Melissa Officer | Sold (automatic/other) | -929 0.02% of company | sold 3.3% | 27K | $2K at $1.95 | Apr 1, 26 |
Tosca Melissa Officer | Acquired (grant/award) | +7K 0.1% of company | added 31% | 28K | n/a | Mar 6, 26 |
Strem Brian M. Officer | Acquired (grant/award) | +17K 0.4% of company | added 36% | 63K | n/a | Mar 6, 26 |
Daniels Eric Joseph Officer | Acquired (grant/award) | +7K 0.1% of company | added 25% | 33K | n/a | Mar 6, 26 |
Strem Brian M. Officer | Sold (automatic/other) | -238 | sold 0.5% | 46K | $481 at $2.02 | Mar 3, 26 |
Daniels Eric Joseph Officer | Sold (automatic/other) | -238 | sold 0.9% | 26K | $481 at $2.02 | Mar 3, 26 |
Strem Brian M. Officer | Acquired (grant/award) | +16K 0.4% of company | added 53% | 46K | n/a | Apr 1, 25 |
Daniels Eric Joseph Officer | Acquired (grant/award) | +8K 0.2% of company | added 42% | 26K | n/a | Apr 1, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on KPRX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for KPRX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
KPRX last traded at $1.66, down 4.05% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Kiora Pharmaceuticals, Inc. Common Stock (KPRX) is next expected to report earnings on Friday, November 6, 2026, about 2 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The KPRX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged KPRX 8 times in the last 30 days.
KPRX (Kiora Pharmaceuticals, Inc. Common Stock) trades on XNAS, with a market cap of about $8M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge KPRX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$KPRX discussion
Sign in to ask a question or join the discussion.